BioSpace News Archive

Applied Genetic Technologies Corporation reported updated interim three-month pediatric results and additional adult safety results out to as long as 24 months from its ongoing Phase 1/2 dose escalation study of AGTC-401.

Gritstone bio, Inc. announced that Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive Officer, will participate in a panel discussion on the role and future of precision oncology at the 2022 BIO CEO & Investor Conference, taking place at the Marriott Marquis in New York City from February 14 to 15 and virtually through February 17, 2022.

CareDx, Inc. announced that it has submitted insights from over 250 kidney, heart, lung, and liver transplant patients to the Centers for Medicare and Medicaid Services in response to their Request for Information on the “Health and Safety Requirements for Transplant Programs, Organ Procurement Organizations, and End-Stage Renal Disease Facilities.”.

Bausch Health, Canada, part of Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC), (“Bausch Health” or the “Company”) today announced the availability through pharmacies across Canada of its new prescription treatment TRULANCE® (plecanatide).

Swedish biotech company Salipro Biotech AB announced that the European Patent Office has granted a further European Patent to the company, No. EP 3 043 814 B1 entitled “Antigen and method for production thereof”, following the approval of the US-member of this patent family already in 2018 under US Patent 10,159,729 B2.

Alkermes plc (Nasdaq: ALKS) today announced positive topline results from ENLIGHTEN-Early, a phase 3b study that evaluated the effect of LYBALVI ®.

908 Devices Inc., a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, announced it will participate in the following virtual investor conferences.

Arrakis Therapeutics today announced that Michael Gilman, Ph.D., Chief Executive Officer, will present a corporate overview at the Guggenheim Healthcare Talks Oncology Conference on Friday, February 11, 2022 at 10:00 a.m. ET.

Cytovale has received additional funding from Biomedical Research and Development Authority (BARDA) to help advance the company’s 10-minute IntelliSep ™ sepsis risk stratification test towards commercial launch.

Sonnet BioTherapeutics Holdings, Inc. announced today its financial results for the three months ended December 31, 2021 and provided a business update.